First Quadrant’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-22,272
| Closed | -$1.62M | – | 293 |
|
|
2021
Q4 | $1.62M | Buy |
22,272
+800
| +4% | +$55.1K | 0.17% | 116 |
|
|
2021
Q3 | $1.5M | Buy |
21,472
+3,600
| +20% | +$253K | 0.18% | 115 |
|
|
2021
Q2 | $1.23M | Hold |
17,872
| – | – | 0.14% | 142 |
|
|
2021
Q1 | $1.16M | Hold |
17,872
| – | – | 0.12% | 153 |
|
|
2020
Q4 | $1.04M | Hold |
17,872
| – | – | 0.1% | 159 |
|
|
2020
Q3 | $1.13M | Hold |
17,872
| – | – | 0.14% | 132 |
|
|
2020
Q2 | $1.38M | Sell |
17,872
-1,000
| -5% | -$76.6K | 0.18% | 134 |
|
|
2020
Q1 | $1.41M | Sell |
18,872
-3,300
| -15% | -$228K | 0.21% | 124 |
|
|
2019
Q4 | $1.44M | Hold |
22,172
| – | – | 0.12% | 170 |
|
|
2019
Q3 | $1.41M | Sell |
22,172
-21,100
| -49% | -$1.38M | 0.13% | 166 |
|
|
2019
Q2 | $2.92M | Sell |
43,272
-2,925
| -6% | -$192K | 0.2% | 124 |
|
|
2019
Q1 | $3M | Sell |
46,197
-1,000
| -2% | -$66.5K | 0.23% | 100 |
|
|
2018
Q4 | $2.95M | Hold |
47,197
| – | – | 0.24% | 97 |
|
|
2018
Q3 | $3.64M | Hold |
47,197
| – | – | 0.08% | 240 |
|
|
2018
Q2 | $3.34M | Hold |
47,197
| – | – | 0.06% | 270 |
|
|
2018
Q1 | $3.56M | Sell |
47,197
-6,405
| -12% | -$509K | 0.07% | 258 |
|
|
2017
Q4 | $3.84M | Sell |
53,602
-13,563
| -20% | -$1.03M | 0.07% | 271 |
|
|
2017
Q3 | $5.44M | Sell |
67,165
-1,064
| -2% | -$81.4K | 0.11% | 242 |
|
|
2017
Q2 | $4.83M | Sell |
68,229
-175,737
| -72% | -$11.7M | 0.1% | 235 |
|
|
2017
Q1 | $16.6M | Sell |
243,966
-186,801
| -43% | -$13.1M | 0.33% | 119 |
|
|
2016
Q4 | $30.8M | Buy |
430,767
+346,697
| +412% | +$25.8M | 0.63% | 23 |
|
|
2016
Q3 | $6.65M | Sell |
84,070
-85,912
| -51% | -$6.98M | 0.14% | 207 |
|
|
2016
Q2 | $14.2M | Sell |
169,982
-47,600
| -22% | -$4.22M | 0.31% | 106 |
|
|
2016
Q1 | $20M | Sell |
217,582
-18,176
| -8% | -$1.64M | 0.44% | 76 |
|
|
2015
Q4 | $23.9M | Sell |
235,758
-359,207
| -60% | -$37.4M | 0.52% | 58 |
|
|
2015
Q3 | $58.4M | Buy |
594,965
+38,676
| +7% | +$4.3M | 1.31% | 9 |
|
|
2015
Q2 | $65.1M | Buy |
556,289
+216,782
| +64% | +$23.7M | 1.37% | 8 |
|
|
2015
Q1 | $33.3M | Sell |
339,507
-220,650
| -39% | -$22.4M | 0.69% | 38 |
|
|
2014
Q4 | $52.8M | Buy |
560,157
+11,694
| +2% | +$1.21M | 1.11% | 12 |
|
|
2014
Q3 | $58.4M | Buy |
548,463
+94,590
| +21% | +$9.26M | 1.31% | 9 |
|
|
2014
Q2 | $37.6M | Buy |
453,873
+257,262
| +131% | +$20M | 0.84% | 23 |
|
|
2014
Q1 | $13.9M | Sell |
196,611
-6,234
| -3% | -$489K | 0.32% | 96 |
|
|
2013
Q4 | $15.2M | Sell |
202,845
-2,126
| -1% | -$148K | 0.36% | 90 |
|
|
2013
Q3 | $12.9M | Buy |
204,971
+26,609
| +15% | +$1.59M | 0.33% | 97 |
|
|
2013
Q2 | $9.14M | Buy |
+178,362
| New | +$9.3M | 0.24% | 124 |
|
Other funds holding GILD
First Quadrant's GILD Position: Q1 2022 in Review
First Quadrant sold out of Gilead Sciences (GILD) in Q1 2022, closing a stake of 22,272 shares — an estimated $1.62M sold.
First Quadrant first reported a position in GILD in Q2 2013 and held it in 35 quarters. The position peaked at $65.1M in Q2 2015. 1,601 funds tracked by Wall St. Rank hold GILD as of Q1 2022.
- First Quadrant reported no remaining Gilead Sciences position as of Q1 2022 after selling out during the quarter.
- First Quadrant sold 22,272 Gilead Sciences shares in Q1 2022, an estimated $1.62M.
- First Quadrant first reported a position in Gilead Sciences in Q2 2013 and held it in 35 quarters.
- First Quadrant's Gilead Sciences position peaked at $65.1M in Q2 2015.
- 1,601 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2022.
Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.